1st July 2008
Prostate Cancer gene 3 (PCA3) is a new gene-based test carried out on a urine sample. PCA3 is highly specific to prostate cancer and this gene is overexpressed in over 95% of prostate cancer cases. This is in contrast to PSA (prostate specific antigen, the blood test that is most commonly used to look for evidence of prostate cancer) which may be increased by conditions such as benign enlargement of the prostate (BPH or BPE) or inflammation of the prostate (prostatitis). The PCA3 test result is not affected by these conditions. To read more about PCA3, please click here.